in-PharmaTechnologist presents its round-up of the latest appointments in the pharmaceutical industry, including news from BIO, Natrix, Amarantus and 3M.
Joanne Duncan and Cathleen Enright have joined the management team at Biotechnology Industry Organization (BIO).
Duncan, BIO’s chief financial officer (CFO) and VP for finance and administration, was previously senior vice president and CFO for the Credit Union National Association (CUNA).
New executive VP, food and agriculture Enright joins the organisation from Western Growers Association (WGA) where she served as vice president for federal government affairs.
3M Drug Delivery Systems have drafted in James Ingebrand as the new VP and general manager.
Ingebrand has enjoyed a 27-year career at 3M, where he was most recently key account manager.
In his new role he will take control of the company’s strategy for inhalation, transdermal, topical and oral drug delivery devices and components.
Brad Sauer, executive VP of 3M health care business said: “Jim’s depth of knowledge and understanding of the pharmaceutical industry equip him with outstanding tools to cultivate the innovation that 3M Drug Delivery Systems is known for.”
Natrix Separations has announced changes in its leadership team, including John Chickosky as president and CEO and Molly McGlaughlin as VP of business development.
Most recently chief commercial officer and president of the bioSystems division of Xcellerex, Chickosky has been a member of the Natrix board of directors since mid-2010. He will continue to hold a board seat.
McGlaughlin joined Natrix in June 2011. She joins the firm from her role as VP of sales and business development at Cytovance Biologics.
The news comes as the biotech prepares for its focused product development effort on a new downstream bioprocessing technology based on its patented advective chromatography platform.
Amarantus BioSciences has named Gerald Commissiong as president and CEO.
In 2008, Commissiong co-founded the biotech with John Commissiong, and acquired the intellectual property rights to the firm’s key protein MANF.
Since then he has served as the company’s chief business officer, as well as a member of the board of directors.
He replaces Martin Cleary, who will remain as chairman of the board.
Commissiong said: “I intend to establish a focused corporate structure centered on our core competencies in the areas of Parkinson's disease and neuroscience.”
PathForward Oncology – a recently created joint venture between CareCore National and D3 Oncology Solutions – have hired Brian Litten as its first CEO.
In this new role, Litten will oversee the company’s goal to forge partnerships between physicians who provide cancer care and health insurance companies.
Prior to joining PathForward, Litten served as VP of strategic and external affairs for a subsidiary of Independence Blue Cross in Philadelphia.
“PathForward pathways provide better outcomes for patients, reward physician participation and lower overall medical costs,” said Litten. “In this rapidly changing American health care system, it's extremely rewarding to lead an organization that has a proven track record of addressing these issues.”